Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed CLL diagnosis and active CLL requiring treatment~* considered inappropriate for fludarabine-based therapy~* not been treated for CLL before~* fully active at a minimum or fully capable of selfcare and up and about more than 50% of waking hours~* age 18yrs or older~* signed written informed consent~Exclusion Criteria:~* prior CLL therapy~* abnormal/inadequate blood values, liver, and kidney function~* certain heart problems, active or chronic infections, serious significant diseases, active autoimmune hemolytic anemia (AIHA) requiring treatment, other current cancer or within last 5 years~* CLL transformation~* CLL central nervous system involvement~* current participation in other clinical study~* inability to comply with the protocol activities~* lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ofatumumab + chlorambucil (Type: EXPERIMENTAL): ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
- chlorambucil (Type: ACTIVE_COMPARATOR): chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).